PharmaEngine, Inc. and Sentinel Oncology Limited enter into an exclusive collaboration and license agreement for SOL-578, a Chk1 inhibitor ... Dec 04
Antibody-drug conjugate for treating different type of Cancers, starts second phase trial... Aug 25
-Advertisements-